Learning From Danish Leaders: Openness, Engagement And Balance
Five Danish Biopharma Leaders Reflect On The Benefits And Limitations Of Their Country's Approach To Management
Executive Summary
Astute students of leadership can glean something from every approach. In Vivo asked five Danish biopharma executives to reflect on what characterizes Danish leadership. They shared insights on the defining features of a Danish approach, its pros and cons, and what lessons they can offer leaders from other countries.
You may also be interested in...
AI Driving Innovation: Insights From Exscientia CEO Andrew Hopkins
Andrew Hopkins, founder and CEO of Exscientia, invented and championed an algorithmic approach to drug design and drug discovery. He talks to In Vivo about artificial intelligence in the biopharma industry today and what lies ahead.
Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.
Rethinking Commercialization Models In The Age Of Pricing And Access Complexity
In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.